Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Anthrax--where does the real threat lie?

Senior K.

Lancet Infect Dis. 2012 Jun;12(6):436-7. No abstract available.

PMID:
22811982
2.
3.

Anthrax threat: a review of clinical and diagnostic measures.

Alqurashi AM.

J Egypt Soc Parasitol. 2013 Apr;43(1):147-66. Review.

PMID:
23697023
4.
5.

The threat of bioterrorism.

Berger DS.

Posit Aware. 2003 Mar-Apr;14(2):40-1. No abstract available.

PMID:
12693375
6.

Pediatric anthrax clinical management: executive summary.

Bradley JS, Peacock G, Krug SE, Bower WA, Cohn AC, Meaney-Delman D, Pavia AT; AAP Committee on Infectious Diseases and Disaster Preparedness Advisory Council.

Pediatrics. 2014 May;133(5):940-2. doi: 10.1542/peds.2014-0564. No abstract available.

7.

Bioterrorism: what level is the threat and are vaccines the answer?

Smith LA.

Expert Rev Vaccines. 2004 Oct;3(5):493-5. No abstract available.

PMID:
15485326
8.

Anthrax countermeasures: current status and future needs.

Borio LL, Gronvall GK.

Biosecur Bioterror. 2005;3(2):102-12.

PMID:
16000041
9.

Anthrax prevention and treatment: utility of therapy combining antibiotic plus vaccine.

Klinman DM, Yamamoto M, Tross D, Tomaru K.

Expert Opin Biol Ther. 2009 Dec;9(12):1477-86. doi: 10.1517/14712590903307347. Review.

PMID:
19769541
10.

Responding to a small-scale bioterrorist anthrax attack: cost-effectiveness analysis comparing preattack vaccination with postattack antibiotic treatment and vaccination.

Schmitt B, Dobrez D, Parada JP, Kyriacou DN, Golub RM, Sharma R, Bennett C.

Arch Intern Med. 2007 Apr 9;167(7):655-62.

PMID:
17420423
11.

Preattack vaccination against anthrax may be cost-effective in certain populations.

Hopkins RJ, Waytes TA, Zink TK.

Arch Intern Med. 2008 Jan 14;168(1):114-5; author reply 115. doi: 10.1001/archinternmed.2007.27. No abstract available.

PMID:
18195210
12.

Recent Developments in Anti-dotes Against Anthrax.

Dhasmana N, Singh LK, Bhaduri A, Misra R, Singh Y.

Recent Pat Antiinfect Drug Discov. 2014;9(2):83-96. Review.

PMID:
25174439
13.

Learning from the 2001 anthrax attacks: immunological characteristics.

Hadler JL.

J Infect Dis. 2007 Jan 15;195(2):163-4. Epub 2006 Dec 6. No abstract available.

PMID:
17191158
14.

Vaccines: countering anthrax: vaccines and immunoglobulins.

Grabenstein JD.

Clin Infect Dis. 2008 Jan 1;46(1):129-36. doi: 10.1086/523578. Review.

PMID:
18171228
15.

A mathematical simulation of the inflammatory response to anthrax infection.

Kumar R, Chow CC, Bartels JD, Clermont G, Vodovotz Y.

Shock. 2008 Jan;29(1):104-11.

16.

Anthrax as a biological weapon: an old disease that poses a new threat.

Tasota FJ, Henker RA, Hoffman LA.

Crit Care Nurse. 2002 Oct;22(5):21-32, 34; quiz 35-6. Review. No abstract available.

17.

Guidelines for treatment of anthrax.

Meyerhoff A, Murphy D.

JAMA. 2002 Oct 16;288(15):1848-9; author reply 1848-9. No abstract available.

PMID:
12377082
18.

Guidelines for treatment of anthrax.

Tice AD.

JAMA. 2002 Oct 16;288(15):1848; author reply 1848-9. No abstract available.

PMID:
12377080
19.

Bioterrorism threat becomes reality.

Ready T.

Nat Med. 2001 Nov;7(11):1167. No abstract available.

PMID:
11689863
20.

Engineered chloroplasts as vaccine factories to combat bioterrorism.

Streatfield SJ.

Trends Biotechnol. 2006 Aug;24(8):339-42. Epub 2006 Jul 11.

PMID:
16815579

Supplemental Content

Support Center